
Dental CAD/CAM Materials and Systems Patent Landscape Report and Forecast 2024-2032
Description
Dental CAD/CAM Materials and Systems Patent Landscape Report and Forecast 2024-2032
Macular Degeneration Drug Pipeline Analysis 2024
The market is significantly driven by the increasing prevalence of macular degeneration, affecting nearly 20 million Americans and around 200 million people around the world.
Advances in diagnostic imaging, such as OCT and AI-enhanced detection, are improving early diagnosis and monitoring. The development of gene and stem cell therapies offers promising long-term or curative treatments. Additionally, the market is witnessing increased investment in R&D and a surge in regulatory approvals for innovative drugs targeting both wet and dry AMD. These trends underscore a dynamic landscape focused on enhancing patient outcomes and reducing the disease burden.
Key Takeaways
- Major companies involved in the macular degeneration drug pipeline market are CHABiotech CO., Ltd., F. Hoffmann-La Roche AG, GSK Plc., Allegro Ophthalmics, LLC, Bayer AG, IVERIC bio, Inc., Allergan Inc., and others.
- Current drug pipeline for macular degeneration includes OCU410, RGX-314, Izervay (avacincaptad pegol), among others.
- Regulatory agencies are providing support through fast-track approvals and special designations for promising new treatments. This regulatory environment encourages the rapid development and availability of innovative therapies for patients in need.
The pipeline analysis for macular degeneration drugs, as covered in the report, offers a comprehensive overview of the latest advancements and ongoing clinical trials in the field. The report highlights significant progress in gene therapies, which are being developed to provide long-term or potentially curative treatments for both dry and wet forms of age-related macular degeneration (AMD). Additionally, the analysis covers innovative approaches such as stem cell therapies, aimed at replacing damaged retinal cells, and novel imaging technologies that enhance early diagnosis and treatment monitoring. The competitive landscape is thoroughly examined, detailing collaborations and strategic partnerships that are accelerating research and development. The report also discuss the regulatory milestones achieved by several investigational drugs, underscoring their potential impact on future treatment paradigms. These insights reflect a dynamic and evolving pipeline that holds promise for more effective and less invasive treatment options for patients with macular degeneration.
Macular Degeneration Drug Pipeline Outlook
Macular Degeneration, specifically Age-related Macular Degeneration (AMD), is a medical condition affecting the macula, the central part of the retina, leading to vision loss in the centre of the visual field. It primarily affects older adults and is classified into two types: dry (atrophic) and wet (neovascular or exudative). Dry AMD is more common and progresses slowly, while wet AMD is less common but more severe, characterised by abnormal blood vessel growth under the retina.
In 2023, significant advancements in the treatment of macular degeneration have been made. The FDA approved SYFOVRE (pegcetacoplan injection), the first therapy specifically targeting geographic atrophy (GA), an advanced form of dry AMD. This approval marks a milestone, offering patients a treatment to slow the progression of GA and potentially preserve vision. Additionally, the FDA approved Izervay (avacincaptad pegol intravitreal solution) for geographic atrophy secondary to age-related macular degeneration. Clinical trials demonstrated that Izervay significantly reduces the rate of GA progression, providing a new, effective option for managing this debilitating condition
These approvals and ongoing developments underscore the dynamic and evolving nature of therapeutic options for macular degeneration, providing hope for improved patient outcomes.
Macular Degeneration - Pipeline Drug Profiles
Recent developments in the treatment of macular degeneration have introduced several promising drugs currently in clinical trials, reflecting significant advancements in the field.
- OCU410 by Ocugen Inc. OCU410 is a pioneering one-time gene therapy designed for advanced dry macular degeneration (dry AMD) or geographic atrophy (GA). This therapy aims to modulate multiple pathways involved in dry AMD progression, including lipid metabolism, inflammation, oxidative stress, and complement activation. It is currently undergoing safety and efficacy trials, with the potential to halt disease progression and possibly restore some vision, marking a significant step forward in AMD treatment.
- RGX-314 by Regenxbio RGX-314 is another innovative gene therapy in clinical trials for wet AMD. This therapy targets the reduction of frequent anti-VEGF injections by delivering a gene encoding a monoclonal antibody fragment that neutralizes VEGF activity. By addressing VEGF, RGX-314 aims to provide a more sustainable treatment option, reducing the burden on patients and potentially offering longer-lasting effects compared to traditional therapies.
- Izervay (avacincaptad pegol) Recently approved by the FDA, Izervay targets geographic atrophy secondary to age-related macular degeneration. Clinical trials have demonstrated that Izervay significantly slows disease progression by inhibiting the complement system activity, providing new hope for patients suffering from GA. This approval underscores the drug’s efficacy in addressing one of the advanced forms of AMD, offering a much-needed therapeutic option for patients.
This section of the report covers the analysis of Macular Degeneration Drug based on various segmentations such as:
Breakup by Drug Class
- Anti-VEGF Drugs
- Photodynamic Therapy (PDT)
- Antioxidant Vitamins and Zinc
Breakup by Phase
- According to EMR analysis, Phase II clinical trials dominate the macular degeneration drug pipeline, accounting for a significant portion of ongoing research. With over 550 drugs currently in Phase II, this stage covers the majority share of the total clinical trials conducted, underscoring the robust development efforts in this critical phase.
- Preclinical Phase: Laboratory and animal studies to assess safety and efficacy.
- Phase I: Small-scale human trials focusing on safety and dosage.
- Phase II: Larger trials to evaluate efficacy and side effects.
- Phase III: Large-scale trials to confirm effectiveness, monitor side effects, and compare with standard treatments.
- Phase IV: Post-marketing studies to gather more information on risks, benefits, and optimal use.
Here are a few notable participants involved in macular degeneration research and development:
- CHABiotech CO., Ltd
- F. Hoffmann-La Roche AG
- GSK Plc.
- Allegro Ophthalmics, LLC
- Bayer AG
These advancements represent significant steps forward in macular degeneration treatment, potentially offering more effective and less burdensome options for patients.
Reasons To Purchase This Report
The Macular Degeneration Drug pipeline analysis report offers invaluable insights into the latest advancements and future trends in macular degeneration treatment. It provides detailed evaluations of emerging therapies, pipeline assessment, and competitive landscape analysis, enabling informed investment decisions and strategic planning.
Key Questions Answered in the Macular Degeneration Drug Pipeline Analysis Report
- What is the current state of the macular degeneration drug pipeline?
- How many companies are currently involved in macular degeneration drug development?
- What is the number of drugs in Phase III and Phase IV trials for macular degeneration?
- Which organisations are at the forefront of macular degeneration drug research?
- What are the effectiveness and safety profiles of the drugs in the macular degeneration pipeline?
- What opportunities and challenges exist in the macular degeneration clinical trial landscape?
- Which companies are leading the major clinical trials for macular degeneration drugs?
- Which regions are involved in clinical trials for macular degeneration?
- What are the recent clinical trial results for macular degeneration drugs?
- What are the emerging trends in macular degeneration clinical trials?
Table of Contents
200 Pages
- 1 Introduction
- 2 Executive Summary
- 3 Global Dental CAD/CAM Materials and Systems Market Overview
- 3.1 Global Dental CAD/CAM Materials and Systems Market Historical Value (2017-2023)
- 3.2 Global Dental CAD/CAM Materials and Systems Market Forecast Value (2024-2032)
- 4 Global Dental CAD/CAM Materials and Systems Market Segmentation
- 4.1 Global Dental CAD/CAM Materials and Systems Market (2017-2032) By Type
- 4.1.1 Market Overview
- 4.1.2 Chair-Side System
- 4.1.3 Laboratory System
- 4.2 Global Dental CAD/CAM Materials and Systems Market (2017-2032) by Product
- 4.2.1 Market Overview
- 4.2.2 Equipment
- 4.2.2.1 Milling Machine
- 4.2.2.2 Scanners
- 4.2.2.3 Others
- 4.2.3 Software
- 4.3 Global Dental CAD/CAM Materials and Systems Market (2017-2032) by End User
- 4.3.1 Market Overview
- 4.3.2 Hospitals
- 4.3.3 Dental Clinics
- 4.3.4 Others
- 5 Global Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 Porter’s Five Forces Analysis
- 5.3 PESTEL Analysis
- 5.4 Industry Events, Initiatives, and Trends
- 5.5 Value Chain Analysis
- 6 Global Dental CAD/CAM Materials and Systems Patent Landscape Analysis
- 6.1 Patent Distribution by Publication Year
- 6.2 Patent Distribution by Application Year
- 6.3 Patent Distribution by Priority Year
- 6.4 Analysis by Type of Patent
- 6.4.1 Granted Patents
- 6.4.2 Patent Application
- 6.4.3 Amended Application
- 6.4.4 Search Report
- 6.5 Analysis by Legal Status
- 6.5.1 Active
- 6.5.2 Pending
- 6.5.3 Expired/Discontinued
- 6.6 Analysis by Patent Jurisdiction
- 6.7 Analysis by Patent Age
- 6.8 Analysis by Cooperative Patent Classification (CPC) Codes
- 6.9 Average Time to Publish a Patent
- 6.9.1 By Entities
- 6.9.2 By Jurisdiction
- 6.9.3 By Technology
- 6.10 Analysis by Type of Entity (Academic and Non-Academic)
- 6.11 Analysis by Top Applicants
- 6.12 Analysis by Top Inventors
- 7 Global Dental CAD/CAM Materials and Systems Patent Analysis by Technology
- 7.1 Total Patents by Top Technologies
- 7.2 Time Evolution of Patents by Technology
- 7.3 Emerging Technologies
- 7.4 Patent Segmentation, By Type
- 7.4.1 Time Evolution by Number of Patents
- 7.4.2 Time Evolution by Number of Patent Families
- 7.4.3 Analysis by Type of Entity (Academic vs Non-Academic)
- 7.4.4 Analysis by Top Applicants
- 7.4.5 Analysis by Top Inventors
- 7.5 Patent Segmentation, By Product Type
- *Complete technology list will be provided in the report.
- 8 EMR Patent Valuation Analysis
- 8.1 Assessment Methodology
- 8.2 High Value Patents
- 8.3 Medium Value Patents
- 8.4 Low Value Patents
- 9 Global Dental CAD/CAM Materials and Systems – Top 10 Players Patent Analysis
- 9.1 Top 10 Entities by Number of Patents
- 9.2 Analysis by Publication Year
- 9.3 Analysis by Application Year
- 9.4 Analysis by Priority Year
- 9.5 Analysis by Type of Patent
- 9.6 Analysis by Jurisdiction
- 9.7 Analysis by Cooperative Patent Classification (CPC) Codes
- 9.8 Analysis by Source of Innovation
- 9.9 Analysis by Forward and Backward Citations
- 9.10 Analysis by Legal Status
- 9.11 Analysis by Patent Age
- 9.12 Analysis by Key Inventors
- 9.13 Entity Dynamics
- 9.13.1 Analysis by Type of Player (Academic vs Non-Academic)
- 9.13.2 Analysis by Collaboration
- 9.13.3 Analysis by Technology
- 9.13.4 Newcomers
- 9.13.4.1 Start-up Companies
- 9.13.4.2 Established Companies
- 10 Patent Profile of Key Players
- 10.1 Align Technology Inc
- 10.1.1 Product Portfolio
- 10.1.2 Patent Portfolio by Patent Families
- 10.1.3 Time Evolution of Patents
- 10.1.4 Geographical Patent Coverage
- 10.1.5 Patent Analysis by Technology
- 10.1.6 Patent News and Developments
- 10.1.7 Financial Analysis
- 10.1.8 SWOT Analysis
- 10.2 Ivoclar Vivadent Ag
- 10.3 3m Innovative Properties Co
- 10.4 Dentsply Sirona Inc
- 10.5 Conformis Inc
- 11 Future Trends
- 12 Global Dental CAD/CAM Materials and Systems Landscape (Additional Insight)*
- 12.1 Global Dental CAD/CAM Materials and Systems: Developers Landscape
- 12.1.1 Analysis by Year of Establishment
- 12.1.2 Analysis by Company Size
- 12.1.3 Analysis by Region
- 12.2 Global Dental CAD/CAM Materials and Systems: Product Landscape
- 12.2.1 Analysis by Type
- *Additional insights are not provided in the standard report.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.